title: Evolution of locoregional treatment for peritoneal carcinomatosis: single-center experience of 308 procedures of cytoreductive surgery and perioperative intraperitoneal chemotherapy.
abstract: BACKGROUND
  Peritoneal carcinomatosis imposes an enormous clinical burden to the oncologic community. This study reports the patterns of care of the locoregional approach of cytoreductive surgery (CRS) and perioperative intraperitoneal chemotherapy as a curative procedure for peritoneal carcinomatosis from the experience of a single tertiary center in Australia.
  
  
  METHODS
  We performed a review of clinical records from a prospective database of patients who were treated at the St George Hospital Peritoneal Surface Malignancy Program according to a standard protocol.
  
  
  RESULTS
  A total of 308 CRS were performed in 249 patients with peritoneal surface malignancy; the mean age was 53 years and 55% were women. Over the years, we expanded the age limit for treatment (P = .03), reduced intensive care unit stays (P = .04), reduced amount of blood transfusion (P = .03), treated patients with a higher peritoneal cancer index (P < .001), achieved higher rates of complete cytoreduction (P = .003), increased use of PIC (P < .001), and improved complication rate (P = .02) and mortality rate (P = .01). The median survival of patients treated over the years also improved (P = .001).
  
  
  CONCLUSIONS
  We show the maturity of the treatment of peritoneal carcinomatosis with CRS and perioperative intraperitoneal chemotherapy in our institution after an initial learning curve with expansion of the selection criteria, improved perioperative outcomes, improved surgical results, and long-term survival outcomes.
authors.affiliation: Department of Surgery, University of New South Wales, St George Hospital, Kogarah, Sydney, Australia.
authors.forename: Terence C
authors.initials: TC
authors.lastname: Chua
authors.forename: Winston
authors.initials: W
authors.lastname: Liauw
authors.forename: Akshat
authors.initials: A
authors.lastname: Saxena
authors.forename: Khalid
authors.initials: K
authors.lastname: Al-Mohaimeed
authors.forename: Salawan
authors.initials: S
authors.lastname: Fransi
authors.forename: Jing
authors.initials: J
authors.lastname: Zhao
authors.forename: David L
authors.initials: DL
authors.lastname: Morris
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001063:Appendiceal Neoplasms / Q000473:pathology; D002277:Carcinoma / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary / Q000601:surgery*; D017024:Chemotherapy, Adjuvant; D015179:Colorectal Neoplasms / Q000473:pathology; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced; D007263:Infusions, Parenteral; D033183:Interdisciplinary Communication; D053208:Kaplan-Meier Estimate; D007902:Length of Stay; D008297:Male; D008499:Medical Records; D008654:Mesothelioma / Q000188:drug therapy / Q000601:surgery; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000473:pathology; D059035:Perioperative Period; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary / Q000601:surgery*; D011553:Pseudomyxoma Peritonei / Q000188:drug therapy / Q000601:surgery; D012189:Retrospective Studies; D016896:Treatment Outcome